ClinicalTrials.gg
Enrolling by invitationNCT06095284Updated Nov 3, 2026

Prescribing Trends and Associated Outcomes of Antiepileptic Drugs in US Nursing Homes Surrounding the COVID-19 Pandemic

An observational study in Dementia, sponsored by Virginia Commonwealth University. Enrolling by invitation at 1 site in United States. Open to participants aged 21 Years and older. Per ClinicalTrials.gov, last updated 2026-11-03.

Sponsored by Virginia Commonwealth University · Observational

How we know

Updated Oct 16, 2026Primary completion movedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Other
Enrollment
22,500,000
Ages
21 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 1,051 studies in Dementia with a site in United States — 211 open to participants now, 276 under way, 15 of them phase 3. Dementia · United States.

Planned enrollment
Largest of 200
22,500,000 · median 200
Started
2022
with 87 others
Observational
200 of 1,051
51 open now
Primary completion
2026-11
later than 74 of 275 live
Registered
844th of 1,051
by date

Among the 1,051 studies in Dementia with a site in United States, this one has the largest planned enrollment of the 200 observational ones that give a count, is one of 88 that started in 2022, is one of 200 observational ones, reaches primary completion later than 74 of the 275 other live ones, and was the 844th registered.

Dementia

2,377 studies on the registry are indexed under Dementia; 572 are open to participants now.

Browse Dementia studies →

Open to participants now

211 of the 1,051 studies in Dementia with a site in United States are open now. Recruiting first, the newest first:

206 more — sign in →

All 211 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 382 Dementia studies recruiting now, 242 (63%) set no upper age limit and 25 (7%) stop at 75 or younger; 15 take children under 18; 163 take healthy volunteers.

This study: 21 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 1,051 studies in Dementia with a site in United States, or all of them as a file.
02

Study summary

Since the "National Partnership to Improve Dementia Care" debuted in 2012, almost all long-stay psychoactive prescribing has been graded by CMS, which has correlated to decreased use. However, some national data suggest that while these psychoactive medications are being used less, prescriptions of mood-stabilizing antiepileptic drugs (AEDs) have increased. Unlike all other psychoactive medications, AEDs prescribed in nursing homes are not mandatorily reported to CMS or graded in a quality-measure.

Read the detailed description

Pilot studies from Virginia suggest increases in AEDs are concentrated entirely in dementia patients with no diagnosis of epilepsy and as a purposeful unmonitored alternative to antipsychotics. AEDs are not FDA approved for dementia symptoms, have weak efficacy evidence, and convey serious risk. Increasingly it seems likely that the Partnership's debut was an inflection point where the trend towards unmonitored alternative drugs for dementia symptoms sharply increased. Early Commonwealth data hints that the COVID pandemic represents a second critical point of inflection where the existing transition towards non-superior but unreported drugs is again rapidly accelerating. All outcomes associated with this evolving prescribing phenomenon remain unknown. That said, pilot data suggests that harms may be increasing without benefit, a development with relevance to all invested in improving dementia care including patients, caregivers, and policy makers.

03

Conditions studied

  • Dementia

Browse trials for

Keywords

  • Mood-stabilizing AED's
  • Nursing Home
04

Who can participate

Ages eligible
21 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

The study population will only include de-identified data sets that are eligible for download and analysis and that meet the inclusion and exclusion criteria. Only those 21 years or older will be included.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • All long-stay nursing home residents will be included. We define long-stay nursing home residents as all individuals residing in a nursing facility place of service for more than 100 days
  • All nursing home clinicians prescribing psychoactive drugs will be included.

Exclusion criteria

Exclusion Criteria:

  • Limited to nursing home residents with continuous fee-for-service or Medicare Advantage plans as well as continuous Part D coverage.
  • Residents without continuous fee-for-service insurance (less than 3 percent of nursing home population) will be excluded.
  • Less than 0.2% of nursing home residents are children; still, this study will be restricted to those > 21 years of age.
  • Nursing home residents who are discharged before the end of the quarterly study periods will also be excluded.
  • Residents with discharges for acute hospitalizations followed by facility reentry on the same record will not be excluded.
  • Non-prescribing clinicians and clinicians that do not prescribe psychoactive medications will be excluded.
05

Study design

Observational model
Cohort
Time perspective
Other
Enrollment
22,500,000 participants (estimated)
Patient registry
No

Groups and cohorts

  • All nursing home residents included in the 2009-2021 MDS

    All nursing home residents included in the 2009-2021 MDS

    Other: Pre-Extraction Phase · Other: Extraction Phase · Other: Post-Extraction Phase

  • Nursing home and non-nursing home residents diagnosed with an AD/ADRD condition

    Nursing home and non-nursing home residents diagnosed with an AD/ADRD condition

    Other: Pre-Extraction Phase · Other: Extraction Phase · Other: Post-Extraction Phase

Interventions

  • OtherPre-Extraction Phase

    This intervention requires the following procedures: Submitting data use agreement, MDS request defined and developed, Part D request, CMS public use file request defines and develop questionnaire

  • OtherExtraction Phase

    Procedures include: Access VRDC for 2 years, Crosswalk CMS files and MDS using ID's, Preliminary analysis for validity/accuracy, Request revision/resubmission, Linked dataset created in VRDC and Distribute Questionnaire

  • OtherPost-Extraction Phase

    Procedures include: De-identified data securely stored, analysis, dissemination and knowledge translation

06

What researchers measure

Primary outcomes

  1. Quarterly rate of use and mean dose of AEDs in US nursing homes

    Quarterly rate of use and mean dose of AEDs in US nursing homes 2009-2021

    Time frame: The years 2009 to 2021

Secondary outcomes

  1. Quarterly rate of use of AEDs in US nursing homes for long-stay residents

    Quarterly rate of use of AEDs in US nursing homes for long-stay residents with and without: dementia, seizure-epilepsy, psychiatric diagnoses, neuropathic pain, an appropriate diagnosis for AED use

    Time frame: The years 2009 to 2012

  2. Quarterly rate of adverse health events among US nursing home residents prescribed or not prescribed AEDs

    Quarterly rate of adverse health events among US nursing home residents prescribed or not prescribed AEDs from 2009 to 2021. Adverse health events include: * Detrimental nursing home outcomes including falls, cognitive scores, functional scores, harmful behaviors, weight loss, hospice, death * ER encounters (per 1000 nursing home days) * Hospitalizations (per 1000 nursing home days), potentially avoidable hospitalizations, medication related hospitalizations, costs of hospital care.

    Time frame: The years 2009 to 2021

07

Study locations

1 site
08

Timeline

2 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Sep 2022 (actual). Primary completion is estimated for Nov 2026, 50 months after the start.

Of 272 non-industry observational studies under Dementia, half reached primary completion within 74 months of starting (the median), counting those still running; a quarter within 32 and three quarters within 202. This study's planned 50 months is below that.

Counting every sponsor, half of 294 studies reached it within 65 months; a quarter within 29 and three quarters within 188.

Primary completion moved once since we started tracking on Sep 25, 2026: Jun 2026 → Nov 2026, on Oct 16, 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Oct 19, 2023
First posted
Oct 23, 2023
StartActual
Sep 1, 2022
Primary completionEst.
Nov 30, 2026was Jun 2026
CompletionEst.
Jun 30, 2027
Last update
Nov 3, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Primary completion
Jun 30, 2026→Nov 30, 2026
Oct 16, 2026
Show all 2 updates
  1. Nov 3, 2026
    Minor edits only
    + 1 other change: verification date
  2. Oct 16, 2026
    Primary completion Jun 30, 2026→Nov 30, 2026

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT06095284
Responsible party
Sponsor
First posted
Oct 23, 2023
Start date
Sep 1, 2022
Primary completion
Nov 30, 2026 (estimated)
Completion
Jun 30, 2027 (estimated)
Last update
Nov 3, 2026

Study contacts

Jonathan Winter
principal investigator · Virginia Commonwealth University

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion